Ulcer and gastritis

Endoscopy

Volumn 34, Issue 2, 2002, Pages 104-110

  Wu, J C Y ^a   Sung, J J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL ANTIGEN; BISMUTH; BISMUTH CITRATE; CARBON 13; CELECOXIB; CLARITHROMYCIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HELICOBACTER PYLORI ANTIGEN; INTERLEUKIN 1; METRONIDAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RIFABUTIN; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA;

ANTIGEN DETECTION; BLEEDING DISORDER; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ENDOSCOPIC THERAPY; ERADICATION THERAPY; FECES ANALYSIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE INFECTION; HEALTH CARE COST; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; META ANALYSIS; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMACH CANCER; TREATMENT FAILURE; TREATMENT PLANNING; UREA BREATH TEST;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLARITHROMYCIN; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PRECANCEROUS CONDITIONS; PROTON PUMPS; RIFABUTIN; STOMACH NEOPLASMS;

EID: 0036160045     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-19843     Document Type: Review

References (42)

1. 13C-urea breath test
2. Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori
3. Usefulness of Helicobacter pylori stool antigen test to monitor response to eradication treatment in children
4. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy
5. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: A European multicenter study. The European Helicobacter pylori HpSA Study Group
6. Post-treatment diagnostic accuracy of a new enzyme immunoassay to detect Helicobacter pylori in stools
7. Accuracy of an enzyme immunoassay for the detection of Helicobacter pylori in stool specimens in the diagnosis of infection and posttreatment check-up
8. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection
9. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis
10. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy
11. Third line treatment for Helicobacter pylori: A prospective, culture-guided study in peptic ulcer patients
12. Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies
13. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients: A double-blind placebo-controlled study
14. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia
15. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin
16. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia: A meta-analysis of randomized, controlled trials
17. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group
18. Short course acid suppressive treatment for patients with functional dyspepsia: Results depend on Helicobacter pylori status. The Frosch Study Group
19. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care
20. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: A randomised trial
21. Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: A randomised controlled trial in primary care
22. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions
23. Interleukin-1 polymorphisms associated with increased risk of gastric cancer
24. Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated
25. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: A prospective, randomized study
26. Cure of Helicobacter pylori infection in atrophic body gastritis patients does not improve mucosal atrophy but reduces hypergastrinemia and its related effects on body ECL-cell hyperplasia
27. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus
28. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: Impacts of hiatal hernia and corpus gastritis
29. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: A randomised controlled trial
30. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy
31. Helicobacter pylori eradication dramatically improves inflammation in the gastric cardia
32. Recent nonsteroidal anti-inflammatory drug use increases the risk of early recurrence of bleeding in patients presenting with bleeding ulcer
33. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis
34. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial
35. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
36. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs and the risk of upper gastrointestinal bleeding
37. Expression and cellular localization of COX-1 and -2 in Helicobacter pylori gastritis
38. Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: A prospective placebo-controlled, double-blind randomized trial
39. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen
40. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: A decision analysis
41. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers
42. Drug treatments in upper gastrointestinal bleeding: Value of endoscopic findings as surrogate end points